In the rapidly evolving
When assessing real-world information, it is often not necessary to recollect data within a short period of time. Quantifiable actions, such as how many times a certain drug was prescribed over a certain amount of time rather than subjective opinions, can be collected once and utilized by multiple stakeholders. This is particularly important when collecting data from over-researched markets such as
Specialized market research agencies use their experience and expertize in order to collect data on the most pertinent KPIs in any given market, and waves of data are often readily available at the time you need them. The market expertise that market research agencies apply to their ad hoc studies is of course also applied to the syndicated research they conduct.
Five key benefits of using syndicated research when building a marketing strategy in the hematology-oncology market:
1. Hematology is a niche market within oncology
2. Physicians working in this field are over-researched
3. Pharmacovigilance and adverse event reporting are the responsibility of the market research agency
4. Syndicated research can provide a good quality to cost ratio for studies conducted in emerging markets
5. Study design and reporting can be tailored to your needs
Our hemato-onco market experts are currently arranging free 30-minute consultations to offer you the chance to find out answers to your most pressing questions about this fast-moving market. 
1. Hematology is a niche market within oncology
The hematology market remains a niche market within oncology and as such research budgets can be smaller than for other areas of the oncology. Syndicated research offers an excellent quality to cost ratio for marketers, with large sample sizes and valuable data available for affordable prices.
2. Physicians working in this field are over-researched
Not only is the global population of physicians working in hematology-oncology relatively small, but there are also currently numerous drugs in development in this therapeutic area. As a result, this target population is frequently approached by market researchers for both qualitative insights and real-world data. It is in the interests of all industry stakeholders not to over-research this group of physicians and thus collectively utilize the objective real-world data available via syndicated research.
3. Pharmacovigilance and adverse event reporting are the responsibility of the market research agency
Companies purchasing ad hoc research take full responsibility for pharmacovigilance and adverse events reporting. When purchasing syndicated research, that responsibility falls with the market research agency, increasing the convenience for marketers.
4. Syndicated research can provide a good quality to cost ratio for studies conducted in emerging markets
Conducting market research in hemato-oncology markets across the world can be an expensive undertaking for any marketing team. Purchasing syndicated research is a cost-effective way to attain quick and actionable insights, particularly when you are looking to receive an overview of a new market or compare data from several markets globally.
5. Study design and reporting can be tailored to your needs
Early subscribers to syndicated research often have the opportunity to contribute to the research design and can customize the analysis and final reporting. This allows you to ensure that the syndicated research delivers the key data you require to optimize the results of your campaign.
AplusA has a range of new and ongoing syndicated studies within hemato-oncology including AML, DLBCL, and MM. Find out more about the key points in hemato-oncology in our eBook:
